Lipid Goals in Diabetic Patients. Clinical Implications after Application of a New Formula for LDL-cholesterol Calculation

Walter Masson Juárez, Melína Huerin, Martín Lobo, Gerardo Masson, Dona Websmaster, Natalia Fernández, Gabriel Micali, Mariano Nemec, Cinthia Romero, Graciela Molinero


Background: There are clear recommendations for lipid management in diabetic patients. A new formula for the calculation of LDLcholesterol(LDL-C) would improve the inaccuracy of the Friedewald formula.Objectives: The aim of this study was to analyze the use of statins and the fulfillment of lipid goals in diabetic patients, evaluatingthe consequences of applying a new formula for LDL-C calculation.Methods: This was a descriptive, cross-sectional, multicenter study including type 2 diabetic patients over 18 years of age. LDL-Cwas calculated using the classic Friedewald formula and the new formula. Recommendations of the position document for the appropriateuse of statins from the Argentine Society of Cardiology were followed.Results: A total of 528 patients were included in the study. In secondary prevention, 77.2% of patients received statins (23.4% highintensitystatins) and 36.6% and 36.0% of these patients achieved the goals of LDL-C below 70% mg/dl and non-HDL-C below 100mg/dl, respectively. In 20.8% of patients with LDL-C below 70 mg/dl according to the Friedewald formula, this goal was not attainedwhen the new formula was applied. In primary prevention, 62.2% patients with risk factors or white organ damage received statins(14.7% high-intensity statins) and 20.9% and 20.4% achieved the goals of LDL-C below 70% mg/dl and non-HDL-C below 100 mg/dl. In 27.7% of patients with LDL-C below 70 mg/dl using the Friedewald formula, this goal was not reached when applying the newformula. More patients did not achieve the LDL-C goal with the new formula when the triglyceride level was higher.Conclusion: In this population, the appropriate use of statins and the fulfillment of lipid goals were poor. Applying the new LDL-Cformula optimized the evaluation of these patients.


Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829-41.

Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-96.

Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-16.

Sever PS, Poulter NR, Dahlöf B, Wedel H, Collins R, Beevers G, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care. 2005;28:1151-7.

Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81.

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 Nov 8. pii: S0735-1097(18)39034-X.

Sociedad Argentina de Cardiología. Área de Consensos y Normas. Uso apropiado de estatinas en Argentina. Documento de Posición. Rev Arg Cardiol 2018;86(Sup.1): 1-13

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019 Aug 31. pii: ehz455.

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18:499-502.

Lindsey CC, Graham MR, Johnston TP, Kiroff CG, Freshley A. A clinical comparison of calculated versus direct measurement of low-density lipoprotein cholesterol level. Pharmacotherapy. 2004; 24:167-72.

Tighe DA, Ockene IS, Reed G, Nicolosi R. Calculated low density lipoprotein cholesterol levels frequently underestimate directly measured low density lipoprotein cholesterol determinations in patients with serum triglyceride levels < or =4.52 mmol/l: an analysis comparing the LipiDirect magnetic LDL assay with the Friedewald calculation. Clin Chim Acta. 2006; 365: 236-42.

Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA 2013;310:2061-8.

Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National Lipid Association recommendations for patient centered management of dyslipidemia: part 1-executive summary. J Clin Lipidol 2014;8:473-88.

Garg A, Grundy SM. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N Engl J Med. 1988;318:81–86.

Knopp RH, Frohlich J, Jokubaitis LA, Dawson K, Broyles FE, Gomez-Coronado D. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia. Am J Med. 1994;96(6A):69S-78S.

Berne C, Siewert-Delle A; URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc Diabetol. 2005;4:7.

Cholesterol Treatment Trialists’ (CTT) Collaborators, Kearney PM, Blackwell L, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117-25.

Stegman B, Puri R, Cho L, Shao M, Ballantyne CM, Barter PJ, et al. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care. 2014;37:3114-20.

Breuker C, Clement F, Mura T, Macioce V, Castet-Nicolas A, Audurier Y, et al. Non-achievement of LDL-cholesterol targets in patients with diabetes at very-high cardiovascular risk receiving statin treatment: Incidence and risk factors. Int J Cardiol. 2018;268:195-99.

Gyberg V, De Bacquer D, De Backer G, Jennings C, Kotseva K, Mellbin L, et al. Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology, Cardiovasc Diabetol. 2015;14:133.

Martin SS, Blaha MJ, Elshazly MB, Brinton EA, Toth PP, McEvoy JW, et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol. 2013;62:732-9.

Palmer MK, Barter PJ, Lundman P, Nicholls SJ, Toth PP, Karlson BW. Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: A VOYAGER analysis.Clin Biochem. 2019;64:24-29.

Whelton SP, Meeusen JW, Donato LJ, Jaffe AS, Saenger A, Sokoll LJ, et al. Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol

Martin SS, Giugliano RP, Murphy SA, Wasserman SM, Stein EA, Ceška R, et al. Comparison of low-density lipoprotein cholesterol assessment by Martin/Hopkins estimation, Friedewald estimation, and preparative ultracentrifugation: insights from the FOURIER trial. JAMA Cardiol. 2018;3:749-53.

Lin I, Sung J, Sanchez RJ, Mallya UG, Friedman M, Panaccio M, et al. Patterns of statin use in a real-world population of patients at high cardiovascular risk. J Manag Care Spec Pharm. 2016;22:685-98.

Ziemer DC, Miller CD, Rhee MK, Doyle JP, Watkins C Jr, Cook CB, et al. Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ. 2005;31:564-71.

García Díaz E, Ramírez Medina D, Morera Porras ÓM, Cabrera Mateos JL. Determinants of inertia with lipid-lowering treatment in patients with type 2 diabetes mellitus. Endocrinol Diabetes Nutr. 2019;66:223-31.

Masson W, Lobo M, Manente D, Vitagliano L, Rostán M, Siniawski D, et al. Respuesta a las estatinas en prevención cardiovascular: evaluación de los hiporrespondedores. Rev Argent Cardiol 2014;82:34-41.

Bosomworth NJ. Approach to identifying and managing atherogenic dyslipidemia: A metabolic consequence of obesity and diabetes. Can Fam Physician. 2013;59:1169-80.

Su X, Kong Y, Peng D. Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol Lipids Health Dis. 2019;18(1):134.

Ram N, Ahmed B, Hashmi F, Jabbar A. Importance of measuring non-HDL cholesterol in type 2 diabetes patients. J Pak Med Assoc. 2014;64:124-8.

Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med. 2013;368:1613-24.

Kuiper JG, Sanchez RJ, Houben E, Heintjes EM, Penning-van Beest FJA, Khan I, et al. Use of Lipid-modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands. Clin Ther. 2017;39:819-27.

Arca M, Ansell D, Averna M, Fanelli F, Gorcyca K, Iorga ŞR, et al. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. Atherosclerosis. 2018;271:120-27.

Full Text


  • There are currently no refbacks.

Licencia Creative Commons
The documents published in this journal are under the licencia Creative Commons Atribución-NoComercial-Compartir-Igual 2.5 Argentina.

Revista argentina de cardiología. ISSN en línea 1850-3748. Argentine journal of cardiology (English ed. Online ISSN 2314-2286) Sociedad Argentina de Cardiología. Azcuénaga 980 (C1115AAD),Ciudad Autónoma de Buenos Aires, República Argentina. Tel. (54 11) 4961-6027/8/9 Fax: 4961-6020